Dongmei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dongmei Li has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
Dongdong Cao
9 shared publicationsZemin Pan
8 shared publicationsHuiling Xu
Laboratory of Xinjiang Endemic and Ethnic Diseases, NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, School of Medicine, Shihezi University, Shihezi City, Xinjiang 832002, China | Department of Pathology, Central People’s Hospital of Zhanjiang, Zhanjiang, Guangdong 52400, China
6 shared publicationsLixia Yao
Key Laboratory of Xinjiang Endemic and Ethnic Diseases, School of Medicine, Shihezi University, Shihezi, China
6 shared publicationsYing Li
School of Medicine, Tarim University, Alaer 843300, Xinjiang, China
6 shared publicationsLei Yang
School of Medicine, Hangzhou Normal University, Hangzhou, China
5 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Current Molecular Pharmacology
- Vol. 19 (1) , 74-84
PVT1&EIF4A1 promote metastasis through regulating Notch-1 signaling pathway via STC-1 in gastric cancer
- 1 January 2026
- Published by KEAI Publishing in Current Molecular Pharmacology
- Vol. 19 (1) , 74-84
Open AccessPVT1&EIF4A1 promote metastasis through regulating Notch-1 signaling pathway via STC-1 in gastric cancer
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 1615-1636
Lung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy
Lung cancer remains a leading cause of cancer-related mortality worldwide, largely due to challenges in its early detection and effective management. Despite advances in treatment modalities, the complex nature of lung cancer, characterized by its molecular heterogeneity and resistance mechanisms, underscores the need for innovative approaches. Cell-free RNA (cfRNA) has emerged as a promising biomarker with significant clinical applications in lung cancer diagnosis, monitoring, and precision medicine. We explore key themes including the utility of cfRNA in early detection, differentiation between benign and malignant lung nodules, molecular subtyping, and real-time therapeutic monitoring. Advances in liquid biopsy technologies, particularly non-invasive cfRNA analysis, provide dynamic means of tracking tumor evolution. cfRNA biomarkers such as miRNA, long non-coding RNAs, and circular RNAs offer unique insights into tumor biology, paving the way for personalized treatment strategies. Further, we discuss the application of cutting-edge technologies such as AI-driven analytics, next-generation sequencing, and multi-omics integration, which are enhancing the clinical utility of cfRNA in identifying treatment resistance and improving outcomes in immunotherapy, targeted therapy, and chemotherapy. The review addresses significant challenges facing cfRNA applications, including pre-analytical variability, technical limitations in detection methods, economic constraints, and the lack of standardization in clinical protocols. Through multidisciplinary collaborations and standardized methodologies, significant progress can be made toward integrating cfRNA into routine clinical practice. Emphasis is placed on future research directions, which include validating cfRNA biomarkers across diverse populations, streamlining workflows, and addressing scalability issues for real-world applications. This comprehensive exploration positions cfRNA at the forefront of innovations in lung cancer management, offering a pathway for improved diagnostic accuracy and individualized care.
- 1 December 2025
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 21, 1615-1636
Open AccessLung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy
Lung cancer remains a leading cause of cancer-related mortality worldwide, largely due to challenges in its early detection and effective management. Despite advances in treatment modalities, the complex nature of lung cancer, characterized by its molecular heterogeneity and resistance mechanisms, underscores the need for innovative approaches. Cell-free RNA (cfRNA) has emerged as a promising biomarker with significant clinical applications in lung cancer diagnosis, monitoring, and precision medicine. We explore key themes including the utility of cfRNA in early detection, differentiation between benign and malignant lung nodules, molecular subtyping, and real-time therapeutic monitoring. Advances in liquid biopsy technologies, particularly non-invasive cfRNA analysis, provide dynamic means of tracking tumor evolution. cfRNA biomarkers such as miRNA, long non-coding RNAs, and circular RNAs offer unique insights into tumor biology, paving the way for personalized treatment strategies. Further, we discuss the application of cutting-edge technologies such as AI-driven analytics, next-generation sequencing, and multi-omics integration, which are enhancing the clinical utility of cfRNA in identifying treatment resistance and improving outcomes in immunotherapy, targeted therapy, and chemotherapy. The review addresses significant challenges facing cfRNA applications, including pre-analytical variability, technical limitations in detection methods, economic constraints, and the lack of standardization in clinical protocols. Through multidisciplinary collaborations and standardized methodologies, significant progress can be made toward integrating cfRNA into routine clinical practice. Emphasis is placed on future research directions, which include validating cfRNA biomarkers across diverse populations, streamlining workflows, and addressing scalability issues for real-world applications. This comprehensive exploration positions cfRNA at the forefront of innovations in lung cancer management, offering a pathway for improved diagnostic accuracy and individualized care.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 10519-10545
Dual Regulation and Clinical Application of miR-34 in Virus-Related Tumors Through Anti-Viral Immunity and Tumor Suppression
MiR-34, as an important class of microRNA, plays a dual regulatory role in host antiviral immunity and tumor suppression. Its unique mechanism targeting both viruses and tumors demonstrates significant potential for synergistic therapeutic applications. During viral infection, miR-34 enhances host immune responses by regulating interferon signaling pathways to target IRF3 phosphorylation and NF-κB activation, which leads to the viral replication suppression. In tumor prevention and treatment, miR-34 acts as a downstream effector of the p53 signaling pathway, inducing cell cycle arrest and apoptosis by inhibiting Cyclin D1 and promoting Bax expression, exhibiting the tumor-suppressive roles. Additionally, miR-34 plays a key role in the interactions between viruses and hosts, as well as tumors and the microenvironment, by balancing the expression of inflammatory factors (eg, IL-6, TNF-α). Although miR-34 has shown significant potential in preclinical studies, its clinical application still faces challenges such as low drug delivery efficiency, off-target effects, and safety concerns. Notably, miR-34 mimics have demonstrated potential in tumor trials to restore tumor suppressor functions, offering the promising and novel strategies for combined anti-viral and anti-tumor therapies. In the future, through multi-omics integration, the development of novel nano-delivery systems, and multicenter clinical trials, miR-34 is expected to become a crucial target for viral prevention and precision tumor therapy.
- 1 November 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 10519-10545
Open AccessDual Regulation and Clinical Application of miR-34 in Virus-Related Tumors Through Anti-Viral Immunity and Tumor Suppression
MiR-34, as an important class of microRNA, plays a dual regulatory role in host antiviral immunity and tumor suppression. Its unique mechanism targeting both viruses and tumors demonstrates significant potential for synergistic therapeutic applications. During viral infection, miR-34 enhances host immune responses by regulating interferon signaling pathways to target IRF3 phosphorylation and NF-κB activation, which leads to the viral replication suppression. In tumor prevention and treatment, miR-34 acts as a downstream effector of the p53 signaling pathway, inducing cell cycle arrest and apoptosis by inhibiting Cyclin D1 and promoting Bax expression, exhibiting the tumor-suppressive roles. Additionally, miR-34 plays a key role in the interactions between viruses and hosts, as well as tumors and the microenvironment, by balancing the expression of inflammatory factors (eg, IL-6, TNF-α). Although miR-34 has shown significant potential in preclinical studies, its clinical application still faces challenges such as low drug delivery efficiency, off-target effects, and safety concerns. Notably, miR-34 mimics have demonstrated potential in tumor trials to restore tumor suppressor functions, offering the promising and novel strategies for combined anti-viral and anti-tumor therapies. In the future, through multi-omics integration, the development of novel nano-delivery systems, and multicenter clinical trials, miR-34 is expected to become a crucial target for viral prevention and precision tumor therapy.
- Open Access
- 21 October 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
Macrophage-mediated delivery of ganciclovir nanocomplexes inhibits the pathogenicity of Kaposi’s sarcoma-associated herpesvirus
Kaposi’s sarcoma-associated herpesvirus (KSHV), a member of the γ-herpesvirus family, is associated with the development of various malignancies. Ganciclovir (GCV) is a competitive inhibitor of DNA and can inhibit the synthesis of KSHV viral DNA polymerase. However, the water solubility of GCV makes it difficult to cross the cell membrane. Although nanocarriers are effective in delivering drugs into cells, they still face challenges in penetrating the dense tissue protected by the mucosal barrier. To address this, we developed macrophage-camouflaged nanoparticles as a drug delivery system, leveraging the innate tropism of macrophages to enhance tissue infiltration and therapeutic outcomes. This approach not only improves drug bioavailability but also minimizes off-target toxicity. In this study, we established an in vitro macrophage inflammation model to mimic the in vivo inflammatory microenvironment and employed ZIF-8 nanoparticles to encapsulate GCV, with hyaluronic acid (HA) as a targeting ligand. The in vivo and in vitro safety evaluations confirmed its excellent biocompatibility. The co-culturing experiment of induced macrophages loaded with nanodrugs with KSHV-positive cells showed that it can restrain proliferation and migration ability of KSHV-positive cells, and also reduce the expression of KSHV pathogenic genes. Collectively, our findings proposed a novel strategy utilizing macrophage-mediated delivery of HA/GCV@ZIF-8 nanomaterials to combat KSHV infection.
- 21 October 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
Open AccessMacrophage-mediated delivery of ganciclovir nanocomplexes inhibits the pathogenicity of Kaposi’s sarcoma-associated herpesvirus
Kaposi’s sarcoma-associated herpesvirus (KSHV), a member of the γ-herpesvirus family, is associated with the development of various malignancies. Ganciclovir (GCV) is a competitive inhibitor of DNA and can inhibit the synthesis of KSHV viral DNA polymerase. However, the water solubility of GCV makes it difficult to cross the cell membrane. Although nanocarriers are effective in delivering drugs into cells, they still face challenges in penetrating the dense tissue protected by the mucosal barrier. To address this, we developed macrophage-camouflaged nanoparticles as a drug delivery system, leveraging the innate tropism of macrophages to enhance tissue infiltration and therapeutic outcomes. This approach not only improves drug bioavailability but also minimizes off-target toxicity. In this study, we established an in vitro macrophage inflammation model to mimic the in vivo inflammatory microenvironment and employed ZIF-8 nanoparticles to encapsulate GCV, with hyaluronic acid (HA) as a targeting ligand. The in vivo and in vitro safety evaluations confirmed its excellent biocompatibility. The co-culturing experiment of induced macrophages loaded with nanodrugs with KSHV-positive cells showed that it can restrain proliferation and migration ability of KSHV-positive cells, and also reduce the expression of KSHV pathogenic genes. Collectively, our findings proposed a novel strategy utilizing macrophage-mediated delivery of HA/GCV@ZIF-8 nanomaterials to combat KSHV infection.
- Open Access
Latency-Associated Nuclear Antigen (LANA) Promotes Ferroptosis by Suppressing Nrf2/GPX4 and Upregulating MDM2
Ferroptosis, an iron-dependent cell death driven by lipid peroxidation, is regulated by key mediators including glutathione peroxidase 4 (GPX4) and nuclear factor erythroid 2-related factor 2 (Nrf2). Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes latency-associated nuclear antigen (LANA), a multifunctional protein critical for viral persistence. Although studies reported that KSHV infection enhanced cellular resistance to ferroptosis, the specific role of LANA in this process remains unexplored. Here, we demonstrate that LANA unexpectedly promotes ferroptosis. In KSHV-positive iSLK.219 cells, LANA knockdown significantly attenuated RSL-3-induced ferroptosis, whereas LANA overexpression sensitized HeLa cells to ferroptotic death. Quantitative analysis revealed that LANA-depleted cells exhibited significantly elevated ROS accumulation (p < 0.01), whereas LANA-overexpressing cells maintained reduced ROS levels during challenge with the ferroptosis inducer RSl-3. Mechanistically, LANA suppressed glutathione peroxidase 4 (GPX4) expression, reduced nuclear factor erythroid 2-related factor 2 (Nrf2) expression and impaired its nuclear translocation, and upregulated mouse double minute 2 homolog (MDM2) expression. Pharmacological inhibition of Nrf2 (ML385) or MDM2 (nutlin3a) reversed the ferroptotic effects of LANA knockdown or overexpression, respectively. These findings reveal a pro-ferroptotic role of LANA via Nrf2/GPX4 suppression and MDM2 activation.
Open AccessLatency-Associated Nuclear Antigen (LANA) Promotes Ferroptosis by Suppressing Nrf2/GPX4 and Upregulating MDM2
Ferroptosis, an iron-dependent cell death driven by lipid peroxidation, is regulated by key mediators including glutathione peroxidase 4 (GPX4) and nuclear factor erythroid 2-related factor 2 (Nrf2). Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes latency-associated nuclear antigen (LANA), a multifunctional protein critical for viral persistence. Although studies reported that KSHV infection enhanced cellular resistance to ferroptosis, the specific role of LANA in this process remains unexplored. Here, we demonstrate that LANA unexpectedly promotes ferroptosis. In KSHV-positive iSLK.219 cells, LANA knockdown significantly attenuated RSL-3-induced ferroptosis, whereas LANA overexpression sensitized HeLa cells to ferroptotic death. Quantitative analysis revealed that LANA-depleted cells exhibited significantly elevated ROS accumulation (p < 0.01), whereas LANA-overexpressing cells maintained reduced ROS levels during challenge with the ferroptosis inducer RSl-3. Mechanistically, LANA suppressed glutathione peroxidase 4 (GPX4) expression, reduced nuclear factor erythroid 2-related factor 2 (Nrf2) expression and impaired its nuclear translocation, and upregulated mouse double minute 2 homolog (MDM2) expression. Pharmacological inhibition of Nrf2 (ML385) or MDM2 (nutlin3a) reversed the ferroptotic effects of LANA knockdown or overexpression, respectively. These findings reveal a pro-ferroptotic role of LANA via Nrf2/GPX4 suppression and MDM2 activation.
- 22 March 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70298
Macrophage‐Mediated Delivery of miR‐34a‐5p‐Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma‐Associated Herpesvirus
Kaposi's sarcoma‐associated herpesvirus (KSHV) has been demonstrated to trigger a variety of malignant neoplasms, however, there are currently no targeted pharmaceutical interventions available. MicroRNA(miRNA)‐based antiviral and tumor therapies are frequently utilized, yet the challenges of cellular uptake and susceptibility to degradation underscore the necessity for a delivery system that can effectively combat KSHV. Nonetheless, despite the efficacy of nanocarriers in delivering drugs into cells, they continue to encounter challenges in penetrating the brain. In this study, a macrophage inflammation model was developed to enhance the delivery of miR‐34a‐5p loaded by folic acid‐modified β‐cyclodextrin grafted polyethyleneimine (β‐CD‐PEI‐FA) nanocomposites, based on FA targeted to folate receptors on the surface of macrophages and tumor cells. Both in vivo and in vitro safety evaluations of the nanocarriers were performed, which confirmed the exceptional biocompatibility. Assays involving the coculture of induced nanodrug‐loaded macrophages and KSHV‐positive cells demonstrated the efficient delivery of miR‐34a‐5p into KSHV‐positive cells through macrophages. This delivery led to the inhibition of the proliferation and cell cycle of cocultured KSHV‐positive cells, as well as a significant reduction in the expression of KSHV pathogenic genes RTA and v‐GPCR. Notably, fluorescence imaging of organs revealed the in vivo delivery of nanocomposites into brain tissues, including tumors. Furthermore, immunohistochemistry analysis revealed increased macrophages infiltration in both tumors and brain tissues in xenograft mice. In conclusion, our study presents a pioneering strategy employing macrophages as carriers for delivering β‐CD‐PEI‐FA/miR‐34a‐5p nanocomplexes in anti‐KSHV therapy.
- 22 March 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70298
Macrophage‐Mediated Delivery of miR‐34a‐5p‐Nanoparticles for Pathogenic Inhibition of Kaposi's Sarcoma‐Associated Herpesvirus
Kaposi's sarcoma‐associated herpesvirus (KSHV) has been demonstrated to trigger a variety of malignant neoplasms, however, there are currently no targeted pharmaceutical interventions available. MicroRNA(miRNA)‐based antiviral and tumor therapies are frequently utilized, yet the challenges of cellular uptake and susceptibility to degradation underscore the necessity for a delivery system that can effectively combat KSHV. Nonetheless, despite the efficacy of nanocarriers in delivering drugs into cells, they continue to encounter challenges in penetrating the brain. In this study, a macrophage inflammation model was developed to enhance the delivery of miR‐34a‐5p loaded by folic acid‐modified β‐cyclodextrin grafted polyethyleneimine (β‐CD‐PEI‐FA) nanocomposites, based on FA targeted to folate receptors on the surface of macrophages and tumor cells. Both in vivo and in vitro safety evaluations of the nanocarriers were performed, which confirmed the exceptional biocompatibility. Assays involving the coculture of induced nanodrug‐loaded macrophages and KSHV‐positive cells demonstrated the efficient delivery of miR‐34a‐5p into KSHV‐positive cells through macrophages. This delivery led to the inhibition of the proliferation and cell cycle of cocultured KSHV‐positive cells, as well as a significant reduction in the expression of KSHV pathogenic genes RTA and v‐GPCR. Notably, fluorescence imaging of organs revealed the in vivo delivery of nanocomposites into brain tissues, including tumors. Furthermore, immunohistochemistry analysis revealed increased macrophages infiltration in both tumors and brain tissues in xenograft mice. In conclusion, our study presents a pioneering strategy employing macrophages as carriers for delivering β‐CD‐PEI‐FA/miR‐34a‐5p nanocomplexes in anti‐KSHV therapy.
- Open Access
- 4 January 2025
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 16 (1) , 1-20
Nanocomplex hyaluronic acid/ganciclovir@ZIF-8 for ganciclovir efficient delivery and targeted anti-KSHV treatment
- 4 January 2025
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 16 (1) , 1-20
Open AccessNanocomplex hyaluronic acid/ganciclovir@ZIF-8 for ganciclovir efficient delivery and targeted anti-KSHV treatment
- Open Access
- 2 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12946
Microneedle-Array-Mediated Transdermal Delivery of GCV-Functionalized Zeolitic Imidazolate Framework-8 Nanoparticles for KSHV Treatment
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a variety of the human gamma-herpesvirus that often leads to the occurrence of malignant tumors. In addition, the occurrence of Kaposi’s sarcoma is a major cause of death among AIDS patients. Ganciclovir (GCV) is the most widely used drug against KSHV infection in the clinic. GCV can restrict the in vivo synthesis of DNA polymerase in KSHV, thereby inhibiting the replication of the herpesvirus. However, GCV still suffers from poor specificity and transmembrane capabilities, leading to many toxic side effects. Therefore, developing a drug delivery system that increases GCV concentrations in target cells remains a significant clinical challenge. In this study, zeolite imidazole salt framework-8 (ZIF-8), a biocompatible porous material constructed by coordinating zinc ions and 2-methylimidazole, was used to load GCV. A nano-delivery system with a microneedle structure was also constructed using a polydimethylsiloxane (PDMS) microneedle mold to fabricate MN/GCV@ZIF-8 arrays. These arrays not only offered good skin-piercing capabilities but also significantly inhibited the cleavage and replication of the virus in vivo, exerting an anti-KSHV function. For these reasons, the arrays were able penetrate the skin’s stratum corneum at the tumor site to deliver GCV and play an anti-KSHV role.
- 2 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12946
Open AccessMicroneedle-Array-Mediated Transdermal Delivery of GCV-Functionalized Zeolitic Imidazolate Framework-8 Nanoparticles for KSHV Treatment
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a variety of the human gamma-herpesvirus that often leads to the occurrence of malignant tumors. In addition, the occurrence of Kaposi’s sarcoma is a major cause of death among AIDS patients. Ganciclovir (GCV) is the most widely used drug against KSHV infection in the clinic. GCV can restrict the in vivo synthesis of DNA polymerase in KSHV, thereby inhibiting the replication of the herpesvirus. However, GCV still suffers from poor specificity and transmembrane capabilities, leading to many toxic side effects. Therefore, developing a drug delivery system that increases GCV concentrations in target cells remains a significant clinical challenge. In this study, zeolite imidazole salt framework-8 (ZIF-8), a biocompatible porous material constructed by coordinating zinc ions and 2-methylimidazole, was used to load GCV. A nano-delivery system with a microneedle structure was also constructed using a polydimethylsiloxane (PDMS) microneedle mold to fabricate MN/GCV@ZIF-8 arrays. These arrays not only offered good skin-piercing capabilities but also significantly inhibited the cleavage and replication of the virus in vivo, exerting an anti-KSHV function. For these reasons, the arrays were able penetrate the skin’s stratum corneum at the tumor site to deliver GCV and play an anti-KSHV role.
- Open Access
- 14 November 2024
- Published by Wiley
Latency-associated nuclear antigen (LANA) promotes ferroptosis by suppressing Nrf2 and upregulating MDM2
Ferroptosis is a recently discovered iron-dependent form of programmed cell death, characterized by the accumulation of lipid peroxidation. Latency-associated nuclear antigen (LANA) plays a crucial role in ensuring the survival and proliferation of cells infected with Kaposi’s sarcoma-associated herpesvirus (KSHV). In this study, we investigated the effects of LANA on ferroptosis. Surprisingly, we discovered that LANA promotes ferroptosis, with its downregulation diminishing and upregulation enhancing this process. LANA itself did not alter intracellular reactive oxygen species (ROS) levels; it modulated ROS levels in response to ferroptosis inducers. Cells with reduced LANA levels exhibited significantly elevated ROS levels, whereas cells overexpressing LANA showed lower ROS levels. LANA suppressed the expression of genes crucial for ferroptosis resistance, such as glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1). Additionally, LANA inhibited nuclear factor erythroid 2-related factor 2 (Nrf2) expression, impeding its nuclear translocation, while upregulating the expression of mouse-double minute 2 (MDM2). Inhibitors targeting Nrf2 and MDM2 partially negated the effects of LANA knockdown and overexpression, respectively, on ferroptosis. These findings suggested that LANA promotes ferroptosis and implyed that inducing ferroptosis may represent a new therapeutic strategy in treating KSHV-related tumors.
- 14 November 2024
- Published by Wiley
Open AccessLatency-associated nuclear antigen (LANA) promotes ferroptosis by suppressing Nrf2 and upregulating MDM2
Ferroptosis is a recently discovered iron-dependent form of programmed cell death, characterized by the accumulation of lipid peroxidation. Latency-associated nuclear antigen (LANA) plays a crucial role in ensuring the survival and proliferation of cells infected with Kaposi’s sarcoma-associated herpesvirus (KSHV). In this study, we investigated the effects of LANA on ferroptosis. Surprisingly, we discovered that LANA promotes ferroptosis, with its downregulation diminishing and upregulation enhancing this process. LANA itself did not alter intracellular reactive oxygen species (ROS) levels; it modulated ROS levels in response to ferroptosis inducers. Cells with reduced LANA levels exhibited significantly elevated ROS levels, whereas cells overexpressing LANA showed lower ROS levels. LANA suppressed the expression of genes crucial for ferroptosis resistance, such as glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1). Additionally, LANA inhibited nuclear factor erythroid 2-related factor 2 (Nrf2) expression, impeding its nuclear translocation, while upregulating the expression of mouse-double minute 2 (MDM2). Inhibitors targeting Nrf2 and MDM2 partially negated the effects of LANA knockdown and overexpression, respectively, on ferroptosis. These findings suggested that LANA promotes ferroptosis and implyed that inducing ferroptosis may represent a new therapeutic strategy in treating KSHV-related tumors.
- Open Access
- 8 November 2024
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 17 (1) , 1
Corrigendum to: An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells
In the online version of the article, a change was made in the author's position. The affiliation of Dongmei Li and Jinli Zhang in the online version of the article titled “An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells” has been updated in “Current Molecular Pharmacology,” 2024; 17: e18761429264583 [1]. The original article can be found online at: https://www.eurekaselect.com/article/137219 Original: Huiling Xu1,2,#, Jinghong Huang1,#, Lixia Yao1,#, Wenyi Gu3, Aynisahan Ruzi4, Yufei Ding5, Ying Li6, Weihua Liang1, Jinfang Jiang1, Zemin Pan1, Dongdong Cao1, Naiming Zhou6,7,*, Dongmei Li1,# and Jinli Zhang1,# * Address correspondence to this author at the Institute of Biochemistry, College of Life Sciences, Zijingang Campus, Zhejiang University, Hangzhou, Zhejiang 310058, China; Tel: 86-13588743854; E-mail: zhounaiming@zju.edu.cn #This author has contributed equally to this work Corrected: Huiling Xu1,2,#, Jinghong Huang1,#, Lixia Yao1,#, Wenyi Gu3, Aynisahan Ruzi4, Yufei Ding5, Ying Li6, Weihua Liang1, Jinfang Jiang1, Zemin Pan1, Dongdong Cao1, Naiming Zhou6,7,*, Dongmei Li1,#,* and Jinli Zhang1,#,* * Address correspondence to these authors at the Institute of Biochemistry, College of Life Sciences, Zijingang Campus, Zhejiang University, Hangzhou, Zhejiang 310058, China. Department of Biochemistry and Molecular Biology/Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine 59 North 2nd Road, Shihezi, Xinjiang, 832002 China. Department of Biochemistry and Molecular Biology/Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine 59 North 2nd Road, Shihezi, Xinjiang, 832002 China. Tel: +86-13588743854; E-mail: zhounaiming@zju.edu.cn Tel: +86-993-2057882; E-mail: lidong_abc@126.com, lidongmei@shzu.edu.cn Tel: +86-993-2057882; E-mail: jinli1998@126.com #These authors have contributed equally to this work Erratum For: An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells
- 8 November 2024
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 17 (1) , 1
Open AccessCorrigendum to: An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells
In the online version of the article, a change was made in the author's position. The affiliation of Dongmei Li and Jinli Zhang in the online version of the article titled “An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells” has been updated in “Current Molecular Pharmacology,” 2024; 17: e18761429264583 [1]. The original article can be found online at: https://www.eurekaselect.com/article/137219 Original: Huiling Xu1,2,#, Jinghong Huang1,#, Lixia Yao1,#, Wenyi Gu3, Aynisahan Ruzi4, Yufei Ding5, Ying Li6, Weihua Liang1, Jinfang Jiang1, Zemin Pan1, Dongdong Cao1, Naiming Zhou6,7,*, Dongmei Li1,# and Jinli Zhang1,# * Address correspondence to this author at the Institute of Biochemistry, College of Life Sciences, Zijingang Campus, Zhejiang University, Hangzhou, Zhejiang 310058, China; Tel: 86-13588743854; E-mail: zhounaiming@zju.edu.cn #This author has contributed equally to this work Corrected: Huiling Xu1,2,#, Jinghong Huang1,#, Lixia Yao1,#, Wenyi Gu3, Aynisahan Ruzi4, Yufei Ding5, Ying Li6, Weihua Liang1, Jinfang Jiang1, Zemin Pan1, Dongdong Cao1, Naiming Zhou6,7,*, Dongmei Li1,#,* and Jinli Zhang1,#,* * Address correspondence to these authors at the Institute of Biochemistry, College of Life Sciences, Zijingang Campus, Zhejiang University, Hangzhou, Zhejiang 310058, China. Department of Biochemistry and Molecular Biology/Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine 59 North 2nd Road, Shihezi, Xinjiang, 832002 China. Department of Biochemistry and Molecular Biology/Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine 59 North 2nd Road, Shihezi, Xinjiang, 832002 China. Tel: +86-13588743854; E-mail: zhounaiming@zju.edu.cn Tel: +86-993-2057882; E-mail: lidong_abc@126.com, lidongmei@shzu.edu.cn Tel: +86-993-2057882; E-mail: jinli1998@126.com #These authors have contributed equally to this work Erratum For: An Essential Role of c-Fos in Notch1-mediated Promotion of Proliferation of KSHV-Infected SH-SY5Y Cells